

STANDARD MEDICARE PART B MANAGEMENT

XGEVA (denosumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications¹

1. Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
2. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
3. Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy

B. Compendial Use²

Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. CRITERIA FOR INITIAL APPROVAL

A. **Hypercalcemia of malignancy**¹

Authorization of 6 months may be granted for the treatment of hypercalcemia of malignancy

B. **Multiple myeloma and bone metastases from a solid tumor**¹

Authorization of 12 months may be granted for prevention of skeletal-related events in members with multiple myeloma or bone metastases from solid tumors (e.g., lung cancer)

C. **Giant cell tumor of the bone**¹

Authorization of 12 months may be granted for the treatment of giant cell tumor of bone

D. **Systemic mastocytosis**²

Authorization of 12 months may be granted for the treatment of osteopenia or osteoporosis in patients with systemic mastocytosis

III. CONTINUATION OF THERAPY

Reference number(s)
2392-A

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization for 12 months may be granted when all of the following criteria are met:

- A. The member is currently receiving therapy with Xgeva
- B. The member is receiving the requested medication for an indication listed in Section II
- C. The medication has been effective for treating the diagnosis or condition

IV. REFERENCE

1. Xgeva [package insert]. Thousand Oaks, CA: Amgen Inc.; June 2020.
2. The NCCN Drugs & Biologics Compendium™ © 2019 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed October 13,2020.